Literature DB >> 27627765

Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.

Kelly R Haisley1, Amy E Laird2, Nima Nabavizadeh3, Ken M Gatter4, John M Holland3, Gina M Vaccaro5, Charles R Thomas3, Paul H Schipper6, John G Hunter1, James P Dolan1.   

Abstract

Importance: Pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) may be a clinical prognostic marker of superior outcomes. In patients with esophageal cancer, pCR is associated with increased survival. While mechanisms for increasing the likelihood of pCR remain unknown, in other solid tumors, higher rates of pCR have been associated with longer time intervals between CRT completion and surgical procedures. Objective: To determine the association between time intervals from the completion of CRT to surgical procedure with rates of pCR in patients with esophageal cancer. Design, Setting, and Participants: A prospectively maintained multidisciplinary foregut database was reviewed for consecutively enrolled patients with esophageal cancer from January 2000 to July 2015 presenting for surgical evaluation at a single National Cancer Institute-designated cancer center within a quaternary academic medical center. Interventions: Included patients successfully completed neoadjuvant CRT followed by esophagectomy. Main Outcomes and Measures: Rate of pCR by logistic regression based on a categorized time interval (ie, 0 to 42, 43 to 56, 57 to 70, 71 to 84, 85 to 98, and 99 or more days) from the completion of CRT to surgical resection, adjusted for clinical stage, demographic information, and CRT regimen.
Results: Of the 234 patients who met inclusion criteria, 191 (81.6%) were male, and the median (range) age was 64 (58-70) years; 206 (88.0%) were diagnosed as having adenocarcinoma, and 65 (27.9%) had a pCR. Patients in the 85 to 98-day group had significantly increased odds of a pCR compared with other groups (odds ratio, 5.46; 95% CI, 1.16-25.68; P = .03). No significant differences in survival were seen between time groups overall or among patients with residual tumor. Conclusions and Relevance: This study suggests that a time interval of 85 to 98 days between CRT completion and surgical resection is associated with significantly increased odds of a pCR in patients with esophageal cancer. No adverse association with survival was detected as a result of delaying resection, even in patients with residual tumor.

Entities:  

Mesh:

Year:  2016        PMID: 27627765     DOI: 10.1001/jamasurg.2016.2743

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  11 in total

1.  When to resect following neoadjuvant therapy for esophageal cancer-issues and limitations in addressing this decision.

Authors:  Emmanuel Gabriel; Steven N Hochwald
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma.

Authors:  Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Hanghang Wang; David H Harpole; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2019-10-08       Impact factor: 5.209

3.  The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients.

Authors:  Basem Azab; Francisco Igor Macedo; David Chang; Caroline Ripat; Dido Franceschi; Alan S Livingstone; Danny Yakoub
Journal:  Clin Med Insights Oncol       Date:  2020-07-03

4.  Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy.

Authors:  Leilei Wu; Zhenshan Zhang; Shuo Li; Linping Ke; Jinming Yu; Xue Meng
Journal:  Cancer Manag Res       Date:  2020-10-27       Impact factor: 3.989

5.  Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.

Authors:  Wenwu He; Tianqin Mao; Jiaxin Yan; Xuefeng Leng; Xuyang Deng; Qin Xie; Lin Peng; Qiong Liao; Marco Scarpa; Yongtao Han
Journal:  Ann Transl Med       Date:  2021-04

6.  Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Authors:  Yinkui Wang; Zining Liu; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

7.  Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review.

Authors:  Scott C Fligor; Savas T Tsikis; Sophie Wang; Ana Sofia Ore; Benjamin G Allar; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin Arndt; Mark P Callery; Sidhu P Gangadharan
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

8.  Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery.

Authors:  Yahua Wu; Jiancheng Li
Journal:  Cancer Manag Res       Date:  2021-03-15       Impact factor: 3.989

Review 9.  Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.

Authors:  Runkai Huang; Zhenbin Qiu; Chunwen Zheng; Ruijie Zeng; Wanxian Chen; Simeng Wang; Enmin Li; Yiwei Xu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

10.  Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.

Authors:  F Klevebro; K Nilsson; M Lindblad; S Ekman; J Johansson; L Lundell; N Ndegwa; J Hedberg; M Nilsson
Journal:  Dis Esophagus       Date:  2020-05-15       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.